Next Article in Journal
The Transcriptomic Toolbox: Resources for Interpreting Large Gene Expression Data within a Precision Medicine Context for Metabolic Disease Atherosclerosis
Next Article in Special Issue
Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma
Previous Article in Journal
A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy
Open AccessCommentary

Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer

by 1,2,3,4,* and 1,2
1
Division of Systems Biology & Personalized Medicine, Walter & Eliza Hall Institute (WEHI), Parkville, Victoria 3052, Australia
2
Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
3
Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria 3000, Australia
4
Department of Medical Oncology, The Northern Hospital, Epping, Victoria 3076, Australia
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2019, 9(2), 20; https://doi.org/10.3390/jpm9020020
Received: 11 March 2019 / Revised: 16 April 2019 / Accepted: 23 April 2019 / Published: 26 April 2019
(This article belongs to the Special Issue Biomarkers and Personalized Therapies in Pancreatic Cancer)
It is estimated that pancreatic cancer will be the second leading cause of cancer-related deaths globally by 2030, highlighting the ongoing lack of effective treatment options for this devastating condition. There is a lack of reliable prognostic or predictive markers in pancreatic cancer to guide management decisions, whether for systemic chemotherapy, molecularly targeted therapies, or immunotherapies. To date, the results for targeted agents and immunotherapies in unselected populations of chemo-refractory pancreatic cancer have not met expectations. The reasons for this lack of efficacy of immunotherapy in pancreatic cancer are not completely understood. The challenges in pancreatic cancer include the physical barrier created by the dense desmoplastic stroma surrounding the tumor, chemokine-mediated exclusion of T cells, relatively poorer antigenicity compared to other solid tumors, paucity of infiltrating T cells within the tumor, ultimately leading to an immunosuppressive microenvironment. A better understanding of the role of inflammation in pancreatic cancer, its tumor microenvironment and individualized patient-related features, be they molecular, clinical or histopathological, would enable a more effective tailored approach to the management of pancreatic cancer. In this review, the role of inflammation, the immune tumor microenvironment and potential immune biomarkers in pancreatic cancer are explored. View Full-Text
Keywords: pancreatic cancer; pancreatic ductal adenocarcinoma (PDAC); immune microenvironment; immune biomarkers; personalized cancer care; inflammation; PD1; CTLA-4 pancreatic cancer; pancreatic ductal adenocarcinoma (PDAC); immune microenvironment; immune biomarkers; personalized cancer care; inflammation; PD1; CTLA-4
Show Figures

Figure 1

MDPI and ACS Style

Lee, B.; Gibbs, P. Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer. J. Pers. Med. 2019, 9, 20.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop